Atrial fibrillation and the pharmacological treatment: the role of propafenone

被引:2
作者
Sestito, A. [1 ]
Molina, E. [2 ]
机构
[1] Univ Cattolica Sacro Cuore, Sch Med, Dept Cardiol, I-00168 Rome, Italy
[2] Univ Parma, Sch Med, Dept Pharmacol, I-43100 Parma, Italy
关键词
Atrial fibrillation (AF); Acute onset AF; Prevention of AF recurrences; Antiarrhythmic drugs; Propafenone; SINUS RHYTHM; SUSTAINED-RELEASE; ORAL PROPAFENONE; MANAGEMENT; CONVERSION; EFFICACY; PREVENTION; THERAPY; TRIAL; RISK;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Atrial fibrillation is the most frequent cardiac rhythm disturbance, with prevalence increasing with age. This disease is a major risk factor for ischaemic stroke. The costs resulting from atrial fibrillation are really impressive. Pharmacological agents are the first line therapy for the management of atrial fibrillation. Antiarrhythmic drugs are used to terminate arrhythmias, as acute treatment for conversion of recent onset atrial fibrillation, and to maintain sinus rhythm, as chronic therapy for prevention of atrial fibrillation recurrences. Among antiarrhythmic agents, drugs that inhibit early sodium current (as propafenone) are proven effective in atrial fibrillation. In this review, the most relevant data on propafenone are provided. Discussion: The development of a sustained-release formulation of propafenone allowed to reduce the wide fluctuations in plasma levels observed with the immediate release preparation, improving compliance and adherence to therapy, by simplifying the dosing regimen from 3 to 2 daily doses. Propafenone resulted an effective measure as acute treatment for conversion of recent onset atrial fibrillation, and to maintain sinus rhythm, as chronic therapy for prevention of atrial fibrillation recurrences. In several clinical studies, strong increases of arrhythmia-free periods as well as marked increases in time to recurrence of symptomatic atrial fibrillation, such as paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation were observed. In particular, well-designed clinical studies demonstrated in large patient populations the efficacy of propafenone at several doses. At the suggested doses propafenone is usually well tolerated. Conclusion: The risk of increased occurrence of regular supraventricular arrhythmia or paroxysmal supraventricular tachycardia has been overestimated for propafenone, because this adverse event was seen in all treatment groups, including placebo, with the same (and low) frequency.
引用
收藏
页码:242 / 253
页数:12
相关论文
共 50 条
  • [41] Efficacy and tolerability of oral propafenone versus quinidine in the treatment of recent onset atrial fibrillation: A randomized, prospective study
    Kosior, Dariusz A.
    Kochanowski, Janusz
    Scislo, Piotr
    Piatkowski, Radoslaw
    Postula, Marek
    Rabczenko, Daniel
    Opolski, Grzegorz
    CARDIOLOGY JOURNAL, 2009, 16 (06) : 521 - 527
  • [42] Vernakalant hydrochloride for the treatment of atrial fibrillation
    Kozlowski, Dariusz
    Budrejko, Szymon
    Lip, Gregory Y. H.
    Mikhaildis, Dimitri P.
    Rysz, Jacek
    Raczak, Grzegorz
    Banach, Maciej
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2009, 18 (12) : 1929 - 1937
  • [43] New pharmacological targets and treatments for atrial fibrillation
    Carlsson, Leif
    Duker, Goren
    Jacobson, Ingemar
    TRENDS IN PHARMACOLOGICAL SCIENCES, 2010, 31 (08) : 364 - 371
  • [44] Paroxysmal atrial fibrillation: Which anti-arrhythmic treatment?
    Extramiana, Fabrice
    Messali, Anne
    Moubarak, Ghassan
    Leenhardt, Antoine
    PRESSE MEDICALE, 2010, 39 (06): : 688 - 693
  • [45] Pharmacological cardioversion of atrial fibrillation
    Ehrlich, JR
    Hohnloser, SH
    ZEITSCHRIFT FUR KARDIOLOGIE, 2005, 94 (01): : 14 - +
  • [46] Electrical versus pharmacological cardioversion for emergency department patients with acute atrial fibrillation (RAFF2): a partial factorial randomised trial
    Stiell, Ian G.
    Sivilotti, Marco L. A.
    Taljaard, Monica
    Birnie, David
    Vadeboncoeur, Alain
    Hohl, Corinne M.
    McRae, Andrew D.
    Rowe, Brian H.
    Brison, Robert J.
    Thiruganasambandamoorthy, Venkatesh
    Macle, Laurent
    Borgundvaag, Bjug
    Morris, Judy
    Mercier, Eric
    Clement, Catherine M.
    Brinkhurst, Jennifer
    Sheehan, Connor
    Brown, Erica
    Nemnom, Marie-Joe
    Wells, George A.
    Perry, Jeffrey J.
    LANCET, 2020, 395 (10221) : 339 - 349
  • [47] "Pill in the Pocket" Antiarrhythmic Drugs for Orally Administered Pharmacologic Cardioversion of Atrial Fibrillation
    Reiffel, James A.
    Capucci, Alessandro
    AMERICAN JOURNAL OF CARDIOLOGY, 2021, 140 : 55 - 61
  • [48] Drivers of hospitalization for patients with atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
    Steinberg, Benjamin A.
    Kim, Sunghee
    Fonarow, Gregg C.
    Thomas, Laine
    Ansell, Jack
    Kowey, Peter R.
    Mahaffey, Kenneth W.
    Gersh, Bernard J.
    Hylek, Elaine
    Naccarelli, Gerald
    Go, Alan S.
    Reiffel, James
    Chang, Paul
    Peterson, Eric D.
    Piccini, Jonathan P.
    AMERICAN HEART JOURNAL, 2014, 167 (05) : 735 - U131
  • [49] The Role of Ranolazine in the Treatment of Ventricular Tachycardia and Atrial Fibrillation: A Narrative Review of the Clinical Evidence
    Murai, Kyosuke
    Vasigh, Amir
    Alexy, Tamas
    Toth, Kalman
    Czopf, Laszlo
    BIOMEDICINES, 2024, 12 (08)
  • [50] Role of oral amiodarone in patients with atrial fibrillation and congestive heart failure
    Kawabata, Mihoko
    Hirao, Kenzo
    Hachiya, Hitoshi
    Higuchi, Kouji
    Tanaka, Yasuaki
    Yagishita, Atsuhiko
    Inaba, Osamu
    Isobe, Mitsuaki
    JOURNAL OF CARDIOLOGY, 2011, 58 (02) : 108 - 115